You are here

Article Text

Article menu
Download PDFPDF
Editorial
Clopidogrel and calcium-channel blockers: a clinically important interaction?

https://doi.org/10.1136/hrt.2009.178624

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Funding We are grateful for support from the NIHR Biomedical Research Centre funding scheme.

    • Competing interests NC has received honoraria from Pfizer, manufacturer of the calcium-channel blocker, amlodipine.

    • Provenance and peer review Commissioned; not externally peer reviewed.

    Linked Articles